Want to see AU:CYC full AI Analyst Report?
CYC Stock Chart & Stats
AU$0.98
-AU$0.04(-1.82%)
At close: 4:00 PM EST
AU$0.98
-AU$0.04(-1.82%)
Day’s Range― - ―
52-Week RangeAU$0.45 - AU$1.29
Previous CloseN/A
Volume20.15K
Average Volume (3M)97.64K
Market Cap
AU$72.30M
Enterprise ValueAU$75.74M
Total Cash (Recent Filing)AU$6.63M
Total Debt (Recent Filing)AU$14.92M
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding125,734,146
10 Day Avg. Volume155,345
30 Day Avg. Volume97,642
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)3.98
Price to Sales (P/S)3.34
P/FCF Ratio-5.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.00Price Target Upside2.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.05
Revenue Forecast (FY)AU$47.80M
Bulls Say, Bears Say
Bulls Say
Recurring Consumable RevenueThe business model generates recurring revenue from Technegas patient-dose consumables plus equipment placements and service contracts. This utilization-linked, installed-base revenue creates predictable volume-driven sales and customer lock-in that support steady cash visibility and scalable growth.
Consistent Top-line GrowthSteady revenue growth through 2025 indicates improving commercial traction and broader adoption of Technegas. Durable top-line momentum provides a pathway to leverage fixed investments and installed base utilization, which can support margin recovery if cost structure and pricing are addressed.
Equity Capital BufferA meaningful equity base (~A$27.1m) gives the company a capital buffer to absorb ongoing losses and fund near-term operations. This reduces immediate solvency risk, improves creditor confidence, and enhances the firm’s ability to secure additional financing or execute strategic initiatives while restructuring toward profitability.
Bears Say
Negative Gross Profit And LossesGross profit turning negative in 2025 signals that core product costs exceeded revenue, a fundamental profitability problem. This suggests structural issues in pricing, unit economics, or cost control; unless corrected, it undermines sustainable margins and the business’s ability to convert revenue growth into lasting profits.
Heavy Operating Cash BurnPersistent deeply negative operating and free cash flow (circa -A$17m to -A$19m in 2025) demonstrates material cash burn. This forces dependence on external funding, increases dilution or debt risk, and constrains the company’s ability to invest in sales, service, and R&D needed to scale the installed base and improve margins.
Rising Leverage And Shrinking AssetsMaterial increase in debt alongside declining equity and total assets raises financial leverage and liquidity stress. Higher leverage amplifies financing costs and covenant risk, reduces strategic flexibility, and can limit access to favorable capital when the business still requires investment to correct operational deficits.
Cyclopharm Limited News
CYC FAQ
What was Cyclopharm Limited’s price range in the past 12 months?
Cyclopharm Limited lowest share price was AU$0.45 and its highest was AU$1.29 in the past 12 months.
What is Cyclopharm Limited’s market cap?
Cyclopharm Limited’s market cap is AU$72.30M.
When is Cyclopharm Limited’s upcoming earnings report date?
Cyclopharm Limited’s upcoming earnings report date is Aug 17, 2026 which is in 30 days.
How were Cyclopharm Limited’s earnings last quarter?
Cyclopharm Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.086 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.086.
Is Cyclopharm Limited overvalued?
According to Wall Street analysts Cyclopharm Limited’s price is currently Undervalued.
Does Cyclopharm Limited pay dividends?
Cyclopharm Limited pays a Semiannually dividend of AU$0.008 which represents an annual dividend yield of N/A. See more information on Cyclopharm Limited dividends here
What is Cyclopharm Limited’s EPS estimate?
Cyclopharm Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cyclopharm Limited have?
Cyclopharm Limited has 125,734,146 shares outstanding.
What happened to Cyclopharm Limited’s price movement after its last earnings report?
Cyclopharm Limited reported an EPS of -AU$0.086 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.765%.
Which hedge fund is a major shareholder of Cyclopharm Limited?
Currently, no hedge funds are holding shares in AU:CYC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cyclopharm Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.00 (2.04% Upside)
AU$1.00 (2.04% Upside)
Blogger Sentiment
Bullish
AU:CYC Sentiment 78%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.35%
12-Months-Change
Fundamentals
Return on Equity
-54.48%
Trailing 12-Months
Asset Growth
-25.80%
Trailing 12-Months
Company Description
Cyclopharm Limited
Cyclopharm Limited is an international enterprise specializing in the production and global distribution of medical devices and radiopharmaceuticals, with operations spanning Asia Pacific, Europe, Canada, and other regions. The company's business activities are structured into two principal divisions: Technegas and Molecular Imaging. Through its Technegas segment, Cyclopharm supplies diagnostic apparatus and accompanying consumables critical for clinicians in the identification of pulmonary embolisms, alongside distributing third-party offerings to the broader diagnostic imaging sector. Conversely, the Molecular Imaging division provides advanced radiopharmaceutical agents essential for medical practitioners diagnosing conditions such as cancer, various neurological disorders, and cardiac diseases. Cyclopharm primarily serves nuclear medicine departments. Established in 1986, the company's corporate headquarters are located in Kingsgrove, Australia.
CYC Stock 12 Month Forecast
Average Price Target
AU$1.00
▲(2.04% Upside)
Technical Analysis
Compumedics Limited
―
Micro-X Ltd.
―
EMvision Medical Devices Ltd.
―
OncoSil Medical Ltd
―
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
―